Oxurion NV

OXUR

BE0003846632

Biotechnology & Medical Research

Market Closed - Euronext Bruxelles Other stock markets 11:02:36 2024-04-25 am EDT			5-day change	1st Jan Change
0.0001 ^EUR	0.00%		0.00%	-88.89%

Apr. 12	Oxurion NV Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 06	Oxurion Raises Additional Funds from Convertible Bonds Issue	MT

OXURION SUCCESSFULLY RAISES EUR >10 MILLION FROM LEADING US AND EUROPEAN HEALTHCARE INVESTORS IN A PRIVATE EQUITY PLACEMENT

March 03, 2022 at 02:01 am EST

To read the full press release, please see: Latest news | Oxurion — Advancing Science. Enhancing Vision

Attachment

Project Owl (EN)- Limited version PIPE PR

Latest news about Oxurion NV

Oxurion NV Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 11	CI
Oxurion Raises Additional Funds from Convertible Bonds Issue	Mar. 06	MT
Oxurion Seeks Healthcare Mergers Under New Corporate Strategy	Jan. 23	MT
Belgium's Oxurion Secures Funding, Evades Bankruptcy; CEO/CFO to Step Down	Dec. 29	MT
Oxurion Announces CEO Changes	Dec. 28	CI
Oxurion Announces Management Changes	Dec. 28	CI
Oxurion Announces CFO Changes	Dec. 28	CI
Oxurion NV Discloses Topline Data from Kalahari Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema	Nov. 20	CI
Oxurion Receives EUR1 Million from Atlas Special Opportunities	Nov. 17	MT
Belgium's Oxurion Secures EUR1.5 Million Funding for Clinical Trial	23-10-25	MT
Oxurion NV Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-28	CI
Oxurion Signs Deals to Advance Diabetic Macular Edema Therapy	23-09-11	MT
Oxurion Issues EUR1 Million Bonds to Atlas	23-08-11	MT
Oxurion NV Reaches Enrollment Target in Kalahari Phase 2, Part B Trial of Novel Pkal Inhibitor Thr-149 in Diabetic Macular Edema	23-05-25	CI
Oxurion NV Auditor Raises 'Going Concern' Doubt	23-03-26	CI
Oxurion NV Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-26	CI
Oxurion NV Announces Board Changes	23-03-14	CI
Oxurion NV Provides Update on Recruitment for Kalahari Phase 2, Part B Trial of Novel Pkal Inhibitor THR 149 in Diabetic Macular Edema	23-03-14	CI
Oxurion NV announced that it expects to receive â‚¬20.8 million in funding	23-03-01	CI
Oxurion NV announced that it has received ?11 million in funding from Negma Group Ltd.	23-02-28	CI
Oxurion NV Announces the Continuation of KALAHARI Phase 2, Part B Study in Diabetic Macular Edema Following Interim Analysis	22-12-14	CI
Oxurion NV Announces Interim Analysis for KALAHARI Trial	22-11-18	CI
Oxurion NV Reports Earnings Results for the Half Year Ended June 30, 2022	22-09-05	CI
Oxurion NV Announces Preclinical Presentation on THR-149 at KININ2022	22-06-07	CI
Oxurion Announces Top-Line Results from Part A of Phase 2 INTEGRAL Trial Evaluating THR-687 for Treatment of Diabetic Macular Edema	22-05-09	CI

Oxurion NV is a biopharmaceutical company developing next generation therapies, designed to improve and better preserve vision in patients with retinal disorders including Geographic Atrophy (GA), the leading cause of vision loss in elderly people worldwide. Oxurion NV is aiming to build the leading global franchise in the treatment of Age-related macular degeneration (AMD), based on the successful clinical development of its two novel therapeutics: THR-149, a plasma kallikr ein inhibitor being developed as a potential new standard of care for AMD patients who respond sub-optimally to anti-VEGF therapy, and THR-687, a pan-RGD integrin inhibitor, initially being developed as a potential new standard of care for all AMD patients.

Sector

Biotechnology & Medical Research

Calendar

2024-05-15 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
OXURION NV	-88.89%	616K
IQVIA HOLDINGS INC.	+1.12%	42.59B
MODERNA, INC.	+6.77%	40.65B
LONZA GROUP AG	+45.26%	40.57B
CELLTRION, INC.	-11.96%	26.77B
ICON PUBLIC LIMITED COMPANY	+6.01%	24.81B
ALNYLAM PHARMACEUTICALS, INC.	-24.92%	18.17B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.63%	11.7B
MEDPACE HOLDINGS, INC.	+27.16%	12.05B
UNITED THERAPEUTICS CORPORATION	+7.30%	11.1B

Other Biotechnology & Medical Research

Oxurion NV

Equities

OXUR

BE0003846632

Biotechnology & Medical Research

OXURION SUCCESSFULLY RAISES EUR >10 MILLION FROM LEADING US AND EUROPEAN HEALTHCARE INVESTORS IN A PRIVATE EQUITY PLACEMENT

Latest news about Oxurion NV

Chart Oxurion NV

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Other Biotechnology & Medical Research